Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Canadian lab extends diagnosis capacity:

This article was originally published in Clinica

Executive Summary

Canada's National Microbiology Laboratory (NML) has received its second shipment of biosafety level 4 viruses. The delivery, from Maryland, US, includes more than a dozen reference virus strains. The NML, which specialises in diagnosis and research on what are billed by Health Canada as "some of the world's most dangerous infectious diseases", is located at the Canadian Science Centre for Human and Animal Health, in Winnipeg. The centre is the first facility in the world to accommodate both human and animal health facilities at the highest level of biocontainment, allowing researchers from both the NML and the National Centre for Foreign Animal Disease to collaborate on research into diseases affecting both humans and animals. The NML received its first shipment of biosafety level 4 viruses in June 2000.

You may also be interested in...

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts